All In Biotech

Drug Trial Radar · NCT07851649

A Study to Assess the Bioavailability and Adhesion of Estradiol/Levonorgestrel TDS in Healthy Post-Menopausal Female Participants

A Study to Compare the Bioequivalence and Adhesion Between a Test Estradiol/Levonorgestrel Transdermal Delivery System (0.045 mg Per Day/0.015 mg Per Day) (Corium TDS) and Reference Climara Pro® at the Same Strength (0.045 mg Per Day / 0.015 mg Per Day) for Seven Days in Post-menopausal Female Participants

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

68

Actual

Start

Jul 1, 2026

Primary completion

Sep 29, 2026

Study completion Sep 29, 2026

Sponsor

Lead sponsor
Corium Innovations, Inc.Industry
Sponsor type
Industry
First posted
Oct 1, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Crossover
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 45 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the bioequivalence and adhesion performance of a test estradiol/levonorgestrel transdermal delivery system (TDS) with the reference product, Climara Pro® (estradiol/levonorgestrel transdermal system), following a single 7-day application in healthy postmenopausal female participants. The study will also evaluate the safety and tolerability of the test and reference patches.

Conditions

  • Healthy Female Participants
  • Postmenopause

Interventions

  • Test Estradiol/Levonorgestrel Transdermal Delivery SystemDrug

    Investigational estradiol/levonorgestrel transdermal delivery system containing estradiol 0.045 mg/day and levonorgestrel 0.015 mg/day. A single patch is applied to the upper quadrant of the buttock and worn continuously for 168 hours (7 days).

  • Climara Pro® (Estradiol/Levonorgestrel Transdermal System)Drug

    Reference-listed estradiol/levonorgestrel transdermal system (Climara Pro®) containing estradiol 0.045 mg/day and levonorgestrel 0.015 mg/day. A single patch is applied to the upper quadrant of the buttock and worn continuously for 168 hours (7 days).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Plasma Concentration (Cmax) of Baseline-Corrected EstradiolTime frame: Predose through 288 hours after patch application
  2. Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of Baseline-Corrected EstradiolTime frame: Predose through 288 hours after patch application
  3. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of Baseline-Corrected EstradiolTime frame: Predose through 288 hours after patch application
  4. Maximum Plasma Concentration (Cmax) of LevonorgestrelTime frame: Predose through 288 hours after patch application
  5. Area Under the Plasma Concentration-Time Curve From Time Zero to Last Measurable Concentration (AUC0-t) of LevonorgestrelTime frame: Predose through 288 hours after patch application
  6. Area Under the Plasma Concentration-Time Curve From Time Zero to Infinity (AUC0-inf) of LevonorgestrelTime frame: Predose through 288 hours after patch application
  7. Mean Adhesion Score (MAS)Time frame: Immediately after patch application through 168 hours after patch application

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Lambda Therapeutic Research Ltd.

    Ahmedabad, Gujarat, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.